Angiogenesis inhibitors and immunomodulation in renal cell cancers: the past, present, and future
PharmaCircle is a leading information provider to the life sciences industry, providing pipeline and products intelligence, business prospecting tools, formulation and component details, supply chain insights, and other information solutions to clients
Muscle mass loss during GLP1 receptor agonist therapy prevented with GDF8 and activin A blockade Kokura, Yoji, et al., Science Direct (2024)
Among the most promising are GLP-1 receptor agonists such as semaglutide and liraglutide, and a newer, dual-action medication called tirzepatide
Zou B, Zhuang RX, Sun XY, Liang J
2.6 Analysis of drug sensitivity using the gene set cancer analysis database We investigated the relationship between gene expression and drug sensitivity using the Genomics of Drug Sensitivity in Cancer and Cancer Therapeutics Response Portal (CTRP) datasets, which contain data from cancer cell lines